Colorectal cancer (CRC) and Cardiovascular disease (CVD) represent leading causes of morbidity and mortality in industrialized countries [1]. While they are typically thought of as separate disease entities, there is growing evidence describing the shared pathophysiology between CRC and CVD [2–4]. Given the overlapping risk factor profile, combining preventive therapies for CRC and CVD along with optimizing acute oncologic treatment approaches to minimize CVD events represents a major opportunity to harmonize the management strategies of both diseases.